课题基金 / 基金详情

Efficacy of NSCs in an EAE model of MS

Efficacy of NSCs in an EAE model of MS
NSC 在 MS 的 EAE 模型中的功效
批准号:
10621251
负责人:
G. RASUL CHAUDHRY
金额:
$15.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-15 至 2026-04-30
关键词:
AdultAffectAgingAnimal ModelAnimalsAnti-Inflammatory AgentsAntibodiesBloodBrain-Derived Neurotrophic FactorCASP3 geneCaspaseCell DeathCell TherapyCell TransplantationCellsCentral Nervous SystemChronicClinicalCodeComplexDataDegenerative DisorderDemyelinationsDifferentiation and GrowthDiseaseDisease ProgressionDisease remissionDoseDrug usageEconomicsEngraftmentEnzyme-Linked Immunosorbent AssayEthicsExhibitsExperimental Autoimmune EncephalomyelitisFaceFast BlueGene ExpressionGenerationsGeneticGlial Fibrillary Acidic ProteinGliosisGoalsHomingHumanImmuneImmune responseImmunizationInfiltrationInflammationInflammatoryInflammatory ResponseInvestigationLabelLesionLifeLungMechanicsMesenchymal Stem CellsModelingMolecularMonitorMotorMultiple SclerosisMusMyelin ProteinsNerve DegenerationNerve RegenerationNervous System PhysiologyNeurodegenerative DisordersNeurogliaNeurologicNeuronsNuclear AntigensOlder PopulationOligodendrogliaOrganPathologyPropertyPublic HealthPublishingQuantitative Reverse Transcriptase PCRRecovery of FunctionRegulatory T-LymphocyteResearchRoleSignal PathwaySpinal CordSpleenStainsStem cell transplantSymptomsTechniquesTeratomaTestingTherapeutic EffectTimeTissuesTransplantationWestern Blottingastrogliosiscentral nervous system demyelinating disordercytokineembryonic stem cellenvironmental stressorglial cell-line derived neurotrophic factorimmune cell infiltrateimmunoregulationimprovedinnovationinsightmouse modelmultiple sclerosis treatmentmyelinationnerve stem cellneurobehavioralneurogenesisneuroprotectionneurotrophic factorpost-transplantresponseself-renewalside effectstem cell therapysuccesstranscriptometranscriptome sequencing

项目摘要

项目成果

G. RASUL CHAUDHRY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Multiple sclerosis (MS) is a degenerative disease, which affects the central nervous system (CNS). While most neurodegenerative diseases affect older populations, the onset of MS generally occurs early in life. There is no cure for MS. Currently used drugs have severe side effects. Past attempts to develop cell therapies to treat MS have met with limited success. The major challenges in developing cell therapies include invasive isolation techniques, limited growth and differentiation potential, as well as genetic instability of adult mesenchymal stem cells (MSCs). We have isolated and differentiated highly proliferative and primitive (p) MSCs into neural stem cells (NSCs). In our preliminary studies, transplantation of NSCs significantly reversed the clinical symptoms when transplanted at an early stage of experimental autoimmune encephalomyelitis (EAE) in a mouse model. These findings are very promising and provide a strong “proof of concept” for cell-based treatment of MS. Since we saw substantial improvement in EAE disease with a single cell dose, we hypothesize that multiple doses of NSCs will be more effective in ameliorating chronic EAE disease symptoms and promoting functional recovery. We envision that this innovative approach using NSCs will enhanced the potency of cell therapy as proposed in this study. The specific aims are: 1. To determine the therapeutic effects of repeated doses of NSCs on chronic EAE in mice. We hypothesize that similar to repeated use of drugs, repeated cell therapy treatments will be more efficacious. This hypothesis will be tested by injecting GFP-labeled NSCs in 3 doses to counter chronic EAE induced by MOG immunization in mice. Changes in the disease symptoms and progression will be monitored by performing neurobehavioral, neurological motor function, mechanical threshold response and cold response analyses to assess the effect of cell therapy on the disease progression and remission. 2. To investigate CNS pathology at cellular and molecular levels in NSC transplanted EAE mice. We hypothesized that NSC treatments will reduce inflammation and restore CNS function. Histopathological analysis of the CNS will be performed to access immune cell infiltrates. Composition of cell infiltrates will be assessed by immunohistochemical analysis of CNS sections. Levels of pro- and anti-inflammatory cytokines will be carried to assess the immunomodulatory properties of transplanted NSCs. NSCs are also likely to help in mitigating the imbalance of immune regulatory cells, reduce astrogliosis, and improve myelination. This will be investigated using appropriate cellular and molecular techniques. NSCs also express high level of neurotrophic factors, their role in neuroprotection will be explored. The effect of NSCs on the global gene expression in the CNS of EAE mice will be examined by RNA-seq and validated by qRT-PCR analysis. RNA-seq analysis should help in determining the signaling pathways involved in potential functional recovery of damaged CNS in EAE mice. The results of this research will provide fundamental insights into EAE and also help in developing cell therapies not only for MS but also for other neurodegenerative diseases.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1186/s13287-023-03533-y
发表时间: 2023-10-26
期刊: Stem cell research & therapy
影响因子: 7.5
作者: []
通讯作者:
DOI: 10.3389/fgene.2022.968228
发表时间: 2022
期刊: FRONTIERS IN GENETICS
影响因子: 3.7
作者: [Al-Obaide, Mohammed, Ishmakej, Albi, Brown, Christina, Mazzella, Matteo, Agosta, Patrina, Perez-Cruet, Mick, Chaudhry, G. Rasul]
通讯作者: Chaudhry, G. Rasul
Efficacy of NSCs in an EAE model of MS
  • 批准号:
    10411336
  • 项目类别:
  • 资助金额:
    $15.0万
  • 财政年份:
    2022
  • 负责人:
    G. RASUL CHAUDHRY
  • 依托单位:
海外基金